the promise of antibody-drug conjugates for the treatment of multiple myeloma
Published 2 years ago • 156 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
1:54
antibody-drug conjugates in multiple myeloma: current status and future considerations
-
2:20
antibody-drug conjugates in multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:29
the future of adcs in treating multiple myeloma
-
2:42
novel drug conjugates for multiple myeloma treatment
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
13:19
using the immune system to fight multiple myeloma
-
5:19
what is multiple myeloma?
-
9:25
mgus diagnosis: a step-by-step approach
-
1:59
the rapid evolution of myeloma research & the importance of improving drug accessibility
-
2:30
a new era of treatment for multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
0:57
insights into a novel antibody-drug conjugate in myeloma: hdp-101
-
1:13
antibody-drug conjugates for the treatment of lymphoma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:46
managing patients with high-risk myeloma
-
3:06
multiple myeloma: adcs and bites
-
0:59
future advancements in the treatment of myeloma
-
1:01
car-t: myeloma toxicities